The Biggest IPO of the Year Prompts Huge Insider Buy
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Headquartered in Boston, MA Fiscal year ends December NASDAQ: TRDA entradatx.com
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of genetic medicines. Its proprietary Endosomal Escape Vehicle (EEV) approach is designed to engage intracellular targets long considered inaccessible.
Its lead oligonucleotide programs target Duchenne muscular dystrophy patients amenable to exon 44, 45, 50 and 51 skipping:
- ENTR-601-44 is in the Phase 1/2 ELEVATE-44-201 study, with a planned U.S. adult study, ELEVATE-44-102.
- ENTR-601-45 is in the Phase 1/2 ELEVATE-45-201 study and holds FDA orphan drug designation.
- ENTR-601-50 and ENTR-601-51 are earlier-stage programs.
Clinical studies run in the U.K., EU and U.S., with a long-term extension platform study (ENTR-DMD-202) for participants.
Entrada also partners with Vertex on VX-670, a clinical-stage candidate for myotonic dystrophy type 1. This collaboration is currently the company's only source of revenue.
Beyond neuromuscular disease, the company is expanding preclinical work into inherited retinal and metabolic diseases. This includes ENTR-801 for Usher syndrome type 2A and a planned second ocular clinical candidate. Updated
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of genetic medicines. Its proprietary Endosomal Escape Vehicle (EEV) approach is designed to engage intracellular targets long considered inaccessible.
The Wall Street consensus 12-month price target for TRDA is $18.75.